Plasma Concentrations of Isoniazid and Rifampin Are Decreased in Adult Pulmonary Tuberculosis Patients with Diabetes Mellitus

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2013-08-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1128/AAC.01345-13PMID 23979746PMCID PMC3811326
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The early bactericidal activity of drugs in patients with pulmonary tuberculosis.

  2015cited by this paper
• Effect of Diabetes Mellitus on Pharmacokinetic and Pharmacodynamic Properties of Drugs

  2012cited by this paper
• The association of dental plaque with cancer mortality in Sweden. A longitudinal study

  2012cited by this paper
• Pharmacokinetics of Rifampin in Peruvian Tuberculosis Patients with and without Comorbid Diabetes or HIV

  2012cited by this paper
• Therapeutic Drug Monitoring in the Treatment of Tuberculosis

  2012cited by this paper
• Risk of tuberculosis among people with diabetes mellitus: an Australian nationwide cohort study

  2012cited by this paper
• Therapeutic drug monitoring in the treatment of active tuberculosis.

  2011cited by this paper
• Effect of type 2 diabetes mellitus on the clinical severity and treatment outcome in patients with pulmonary tuberculosis: a potential role in the emergence of multidrug-resistance.

  2011cited by this paper
• Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA

  2010cited by this paper
• Pharmacokinetics of Antituberculosis Drugs in Pulmonary Tuberculosis Patients with Type 2 Diabetes

  2009cited by this paper
• Type 2 diabetes and multidrug-resistant tuberculosis

  2008cited by this paper
• Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis

  2008cited by this paper
• Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence

  2007cited by this paper
• The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis.

  2007cited by this paper
• Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes.

  2006influential reference
• Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients.

  2006cited by this paper
• Diabetes mellitus is strongly associated with tuberculosis in Indonesia.

  2006cited by this paper
• Therapeutic Monitoring of Isoniazid, Pyrazinamide and Rifampicin in Tuberculosis Patients Using LC

  2005cited by this paper
• Semiqualitative Method for Detection of Pesticide Residues Over Established Limits in Vegetables by Use of GC–μECD and GC–(EI)MS

  2005cited by this paper
• Determination of ethambutol in plasma by high-performance liquid chromatography after pre-column derivatization.

  1998cited by this paper
• The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics.

  1997cited by this paper
• The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis.

  1997cited by this paper
• Incidence of pulmonary tuberculosis among diabetics.

  1995cited by this paper

• Population pharmacokinetics of isoniazid in adult Indian tuberculosis patients: Evaluation of NAT2 polymorphisms.

  2026cites this paper
• Parametric Population Pharmacokinetics Model Repository of Rifampicin: Model-Informed Individualized Therapy

  2025cites this paper
• Rifampicin Exposure in Tuberculosis Patients with Comorbidities in Sub-Saharan Africa: Prioritising Populations for Treatment—A Systematic Review and Meta-analysis

  2025cites this paper
• Pharmacokinetics-pharmacodynamics of first-line antitubercular drugs: a comparative study in tuberculosis patients with and without concomitant diabetes mellitus

  2024influential citation
• Tuberculosis patients with diabetes co-morbidity experience reduced Mycobacterium tuberculosis complex clearance

  2024cites this paper
• Study of risk factors and clinical management of patients with clinical non-response due to low plasma levels of anti-tubercular drugs.

  2024cites this paper
• Drug exposure and treatment outcomes in patients with multidrug resistant tuberculosis and diabetes mellitus: A multicenter prospective cohort study from China.

  2024cites this paper
• Level function levels and oxidative stress markers in patients with multidrug-resistant tuberculosis in the Brazilian Amazon.

  2024cites this paper
• Risk factors of adult isoniazid-resistant and rifampicin-susceptible tuberculosis in Nanjing, 2019–2021

  2024cites this paper
• State of the art of real-life concentration monitoring of rifampicin and its implementation contextualized in resource-limited settings: the Tanzanian case

  2024cites this paper
• Pharmacokinetic drug-drug interaction between first-line anti-TB and anti-diabetic drugs in patients with tuberculosis and diabetes mellitus.

  2024cites this paper
• Does diabetes mellitus comorbidity increase the risk of drug-induced liver injury during tuberculosis treatment?

  2023cites this paper
• Pulmonary tuberculosis and diabetes mellitus: Epidemiology, pathogenesis and therapeutic management (Review)

  2023cites this paper
• Association between diabetes mellitus and cause of death in patients with tuberculosis: A Korean nationwide cohort study

  2023cites this paper
• Factores profesionales y conocimiento de la comorbilidad tuberculosis-diabetes en responsables de salud de la Estrategia Sanitaria de Prevención y Control de Tuberculosis

  2023cites this paper
• The Effect of Diabetes Mellitus on the Pharmacokinetics of Tuberculosis Drugs

  2023influential citation
• Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus

  2023cites this paper
• Tuberculoso orchiepididymitus in insulinodependent Type 2 diabetes Mellitus: Case report

  2022cites this paper
• Population pharmacokinetics analyses of rifampicin in adult and children populations: A systematic review

  2022cites this paper
• Tuberculous Orchiepidimitis In InsulinDependent Type 2 Diabetes Mellitus: A Case Report

  2022cites this paper
• Tuberculosis and comorbidities: treatment challenges in patients with comorbid diabetes mellitus and depression

  2022cites this paper
• Impact of diabetes mellitus on rifampicin's plasma concentration and bioavailability in patients with tuberculosis: A systematic review and meta-analysis study.

  2022cites this paper
• Factors associated with tuberculosis-diabetes mellitus type 2 binomial in rural population of Oaxaca, Mexico.

  2022cites this paper
• SNPs in Genes Related to DNA Damage Repair in Mycobacterium Tuberculosis: Their Association with Type 2 Diabetes Mellitus and Drug Resistance

  2022cites this paper
• Effect of serum isoniazid level on treatment outcomes among tuberculosis patients with slow response - A retrospective cohort study.

  2021cites this paper
• TCRM_A_310463 463..470

  2021cites this paper
• LC-MS/MS method for simultaneous quantification of the first-line anti-tuberculosis drugs and six primary metabolites in patient plasma: Implications for therapeutic drug monitoring.

  2021cites this paper
• Prevalence and factors associated with diabetes mellitus among tuberculosis patients in South India—a cross-sectional analytical study

  2021cites this paper
• Tuberculosis Relapse in the Epididymis After the Completion of Nine Months of Anti-Tuberculosis Chemotherapy in a Patient with Poorly Controlled Diabetes Mellitus

  2021cites this paper
• Model‐Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co‐Infected With Tuberculosis and HIV: Implications for a Novel Dosing Strategy

  2020cites this paper
• Imbalance of Drug Transporter-CYP450s Interplay by Diabetes and Its Clinical Significance

  2020cites this paper
• Pharmacokinetics of anti-tuberculosis drugs in multidrug resistant tuberculosis patients in India

  2020cites this paper
• A novel risk factor for predicting anti-tuberculosis drug resistance in patients with tuberculosis complicated with type 2 diabetes mellitus.

  2020cites this paper
• Can diabetes mellitus modify the plasma concentrations of rifampicin in patients under treatment for tuberculosis?

  2020cites this paper
• Diabetes Mellitus and Prediabetes among Patients with Tuberculosis in a Single North Indian Tertiary Care Centre

  2020cites this paper
• Impact of Uncontrolled HbA1C on The Outcome of Tuberculosis Treatment in TB Patients With Diabetes

  2020cites this paper
• Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients

  2019cites this paper
• Anthropometric and genetic factors associated with the exposure of rifampicin and isoniazid in Mexican patients with tuberculosis.

  2019cites this paper
• Reduced moxifloxacin exposure in patients with tuberculosis and diabetes

  2019cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis

  2019cites this paper
• The correlation between CT features and glycosylated hemoglobin level in patients with T2DM complicated with primary pulmonary tuberculosis

  2018cites this paper
• Population/ Nonlinear mixed-effects modelling of pharmacokinetics and pharmacodynamics of tuberculosis treatment

  2018cites this paper
• Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?

  2018influential citation
• Expression and Activity of CYP2C8 and 2C9 in Diabetes Mellitus and Nonalcoholic Fatty Liver Disease

  2018influential citation
• Role of Therapeutic Drug Monitoring in Treatment Optimization in Tuberculosis and Diabetes Mellitus Comorbidity

  2018cites this paper
• Prevalence of tuberculosis and multidrug resistant tuberculosis in the Middle East Region

  2018cites this paper
• Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid

  2018cites this paper
• Effect of Diabetes Mellitus on the Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment

  2018cites this paper
• The development and validation of a LC-MS/MS method for the quantitation of metformin, rifampicin and isoniazid in rat plasma using HILIC chromatography.

  2018cites this paper
• Performance of computed tomography versus chest radiography in patients with pulmonary tuberculosis with and without diabetes at a tertiary hospital in Riyadh, Saudi Arabia

  2018cites this paper
• Oxidative stress and TB outcomes in patients with diabetes mellitus?

  2017cites this paper
• The effect size of type 2 diabetes mellitus on tuberculosis drug resistance and adverse treatment outcomes.

  2017cites this paper
• Factores asociados a la comorbilidad dm-tbc en pacientes atendidos en el consultorio de endocrinología del hospital nacional Hipólito Unánue en el período enero 2010 - junio 2016

  2017cites this paper
• RSSDI clinical practice recommendations for diagnosis, prevention, and control of the diabetes mellitus-tuberculosis double burden

  2017cites this paper
• Clinical and pharmacological hallmarks of rifapentine’s use in diabetes patients with active and latent tuberculosis: do we know enough?

  2017cites this paper
• Diabetes is Associated with Severe Adverse Events in Multidrug-Resistant Tuberculosis.

  2017cites this paper
• Diabetes is Associated with Severe Adverse Events in Multidrug-Resistant Tuberculosis.

  2017cites this paper
• The challenges of pharmacokinetic variability of first-line anti-TB drugs

  2017cites this paper
• Factors Influencing Tuberculosis Treatment Outcome in Adult Patients Treated with Thrice-Weekly Regimens in India

  2017cites this paper
• High prevalence of diabetes and anthropometric heterogeneity among tuberculosis patients in Pakistan

  2017cites this paper
• The effect of diabetes control status on treatment response in pulmonary tuberculosis: a prospective study

  2016cites this paper
• Diabetes and Tuberculosis

  2016cites this paper
• Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring

  2016cites this paper
• HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients

  2016cites this paper
• Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus

  2016cites this paper
• Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis.

  2016cites this paper
• Diabetes-related tuberculosis in the Middle East: an urgent need for regional research

  2015cites this paper
• Rifampin resistance and diabetes mellitus in a cross-sectional study of adult patients in rural South India

  2015cites this paper
• The Influence of Diabetes, Glycemic Control, and Diabetes-Related Comorbidities on Pulmonary Tuberculosis

  2015cites this paper
• Association of Pulmonary Tuberculosis and Diabetes in Mexico: Analysis of the National Tuberculosis Registry 2000–2012

  2015cites this paper
• Effects of type 2 diabetes mellitus on the population pharmacokinetics of rifampin in tuberculosis patients.

  2015cites this paper
• Inhaled clofazimine delivery for the treatment of pulmonary tuberculosis

  2015cites this paper
• [Tuberculosis and diabetes co-morbidity: an unresolved problem].

  2014cites this paper
• Comorbilidad de tuberculosis y diabetes: Problema aún sin resolver

  2014cites this paper
• Impact of diabetes on the natural history of tuberculosis.

  2014cites this paper
• World Journal of Diabetes

  year unknowncites this paper